The CenterWatch Weekly, September 06, 2016
Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) are markedly expanding the reach of the Idiopathic Pulmonary Fibrosis– PROspective Outcomes (IPF-PRO) Registry, the first multicenter longitudinal patient registry for IPF in the U.S. IPF-PRO patient registries can be critical to the understanding and study of unusual diseases, and the development of these registries is on the rise. First launched in 2014 with a goal of enrolling 300 patients at 18 clinical study sites, the registry now aims to increase enrollment to 1,500 patients across 45 sites nationwide.
Biomedical Systems and Foundry Health are partnering to create a cloud-based data management system that delivers clinical trial data in real time. Industry experts believe that cloud-based data management systems for clinical trials offer the potential of greater speed and flexibility, which could reduce costs, increase collaboration between researchers and accelerate the research and development process. The delivery of immediately accessible data could allow researchers to advance trials more quickly—or even address potential problems as soon as they appear.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.